Burke, Muir, Rauschecker, Smithy, Vega receive NCCN Foundation Young Investigator Awards

Roy Herbst receives Ezra Greenspan Award from Chemotherapy+ Foundation

Roy S. Herbst (middle) receives his award at the Innovation Gala of The Chemotherapy+ Foundation, with Robert Winn (left), director and Lipman Chair in Oncology at VCU Massey Comprehensive Cancer Center, and Katerina Politi (right), scientific director of YCC’s Center for Thoracic Cancers.Roy S. Herbst was awarded the Ezra Greenspan Award at the Innovation Gala of The Chemotherapy+ Foundation on Nov. 19 in New York City.

November 22, 2024

Vol.50 No.44

Clinical Roundup

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

The National Comprehensive Cancer Network updated its chronic myeloid leukemia treatment guidelines, recommending Scemblix (asciminib) for the treatment of adults with newly diagnosed Ph+ CML-CP as a category 1-preferred.

November 22, 2024

Vol.50 No.44

In Brief

Judith Kleinerman receives ASH Exemplary Service Award

The American Society of Hematology will recognize Judith Kleinerman as the recipient of the 2024 ASH Exemplary Service Award.

November 15, 2024

Vol.50 No.43

Drugs & Targets

NCCN adds Lymphir to Clinical Practice Guidelines in Oncology

The National Comprehensive Cancer Network added Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy, to the NCCN Clinical Practice Guidelines in Oncology. Lymphir is included based on an NCCN Category 2A recommendation which indicates a uniform NCCN consensus that the drug is appropriate as an option for patients with CTCL.

September 06, 2024

Vol.50 No.33

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.

Fred Hutch announces eight recipients of 2024 Eddie Méndez Scholar Award

Fred Hutch Cancer Center announced the recipients of the 2024 Dr. Eddie Méndez Scholar Award, which recognizes early-career scientists from underrepresented backgrounds who are studying cancer, infectious diseases, and basic sciences.

June 21, 2024

Vol.50 No.25

Burke, Muir, Rauschecker, Smithy, Vega receive NCCN Foundation Young Investigator Awards

YOU MAY BE INTERESTED IN

Roy Herbst receives Ezra Greenspan Award from Chemotherapy+ Foundation

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

Judith Kleinerman receives ASH Exemplary Service Award

NCCN adds Lymphir to Clinical Practice Guidelines in Oncology

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Fred Hutch announces eight recipients of 2024 Eddie Méndez Scholar Award

Renew today!

Subscriber content

Never miss an issue!

Login

Burke, Muir, Rauschecker, Smithy, Vega receive NCCN Foundation Young Investigator Awards

YOU MAY BE INTERESTED IN

Roy Herbst receives Ezra Greenspan Award from Chemotherapy+ Foundation

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

Judith Kleinerman receives ASH Exemplary Service Award

NCCN adds Lymphir to Clinical Practice Guidelines in Oncology

Platinum drugs are off the shortage list, but the underlying problem is unsolvedFDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Fred Hutch announces eight recipients of 2024 Eddie Méndez Scholar Award

Never miss an issue!

Login

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”